CD152 antibody | BNI3
No associated image currently available
Mouse anti Human CD152 antibody, clone BNI3 recognizes human CD152, also known as CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), an inhibitory receptor and negative regulator of T-cell responses. CD152 is a single pass type 1 transmembrane protein belonging to the immunoglobulin superfamily containing a single Ig-v-like domain in the extracellular region.
CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86 (Azuma et al. 1993).
Mouse anti human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line (Steiner et al. 2001) and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Mouse anti Human CD152 antibody, clone BNI3 binds to the same epitope as classified anti CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997).
The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratori et al. 1997, Chikuma et al. 2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface (Valk et al. 2008). CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases (Romo-Tena et al. 2013).
CD152 along with CD28 binds to the co-stimulatory molecules CD80 and CD86 (Azuma et al. 1993).
Mouse anti human CD152 antibody, clone BNI3 is able to block ligand binding on the Raji B-cell line (Steiner et al. 2001) and blocks binding of an alternative clone, BNI8 to CTLA-4/Ig in ELISA. Mouse anti Human CD152 antibody, clone BNI3 binds to the same epitope as classified anti CTLA-4 clones 11D4 and 10A8 (Wang et al. In: Leukocyte typing VI 1997 Garland Publishing Inc. pp97-98, Bull World Health Organ. 1997).
The cytoplasmic domain of CD152 contains a critical tyrosine at residue 201 phosphorylated by Janus Kinase 2 which subsequently controls surface expression through regulation of CD152 interaction with AP-2 (Shiratori et al. 1997, Chikuma et al. 2000). CD152 is expressed primarily as an intracellular antigen with transport to the cell surface under tight regulation of several molecules including Trim, PLD and TIRC7, CD152 also demonstrates rapid internalization once expressed at the cell surface (Valk et al. 2008). CD152 plays a significant role in maintaining tolerance to self antigens and defects in CD152 presentation and expression has been implicated in a number of autoimmune diseases (Romo-Tena et al. 2013).
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - liquid
- Preparation
- Purified by affinity chromatography from ascites
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from ascites
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 0.5% Bovine Serum Albumin - Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
2% Bovine Serum Albumin - Immunogen
- Human CTLA-4/human IgG heavy chain fusion protein.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse P3/X63-Ag8.653 myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC.
DO NOT FREEZE
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 18 months from date of despatch.
- Guarantee
- Guaranteed until date of expiry. Please see product label.
More Information
- UniProt
- P16410 Related reagents
- Entrez Gene
- CTLA4 Related reagents
- GO Terms
- GO:0005887 integral to plasma membrane
- GO:0005794 Golgi apparatus
- GO:0006955 immune response
- GO:0006974 response to DNA damage stimulus
- GO:0009897 external side of plasma membrane
- GO:0030889 negative regulation of B cell proliferation
- GO:0031295 T cell costimulation
- GO:0043065 positive regulation of apoptosis
- GO:0045334 clathrin-coated endocytic vesicle
- GO:0045590 negative regulation of regulatory T cell differentiation
- GO:0048471 perinuclear region of cytoplasm
- GO:0050853 B cell receptor signaling pathway
- Regulatory
- For research purposes only
Applications of CD152 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry 1 | Neat | 1/10 | |
| Immunofluorescence | |||
| Immunohistology - Frozen 2 | 5ug/ml | 50ug/ml | |
| Immunohistology - Paraffin | |||
| Immunoprecipitation | |||
| Flow Cytometry 1 | Neat |
- 1Membrane permeabilization is required for this application. Bio-Rad recommend the use of Leucoperm™ (Product Code BUF09) for this purpose.
- 2The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.
- 1 Membrane permeabilisation is required for this application. Bio-Rad recommends the use of Leucoperm™ (Product Code BUF09) for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
- Flow Cytometry
- Use 20ul of the suggested working dilution to label 5x105 cells in 100ul.
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG2a Negative Control | MCA929 | 100 Tests | F | ||
| Mouse IgG2a Negative Control:RPE | MCA929PE | 100 Tests | F |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | 50 Test | F | ||
| Human Seroblock | BUF070B | 200 Test | F |
Product Specific References
References for CD152 antibody
-
Linsley, P.S. et al. (1992) Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
J Exp Med. 176 (6): 1595-604. -
Kuiper, H.M. et al. (1995) Activated T cells can induce high levels of CTLA-4 expression on B cells.
J Immunol. 155 (4): 1776-83. -
Castan, J. et al. (1997) Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues.
Immunology. 90 (2): 265-71. -
Lee, C.C. et al. (2009) The regulatory function of umbilical cord blood CD4(+) CD25(+) T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15.
Pediatr Allergy Immunol. 20 (7): 624-32. -
Pistillo, M.P. et al. (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.
Blood. 101: 202-9. -
Tan, P.H. et al. (2005) Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression.
Blood. 106: 2936-43. -
Steiner, K. et al. (2001) Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis.
Clin Exp Immunol. 126: 143-50. -
Lu, C.H. et al. (2016) DNA Methyltransferase Inhibitor Promotes Human CD4+CD25hFOXP3+ Regulatory T Lymphocyte Induction under Suboptimal TCR Stimulation.
Front Immunol. 7: 488. -
Steiner, K. et al. (1999) Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.
Clin Exp Immunol. 115 (3): 451-7. -
Ward, F.J. et al. (2013) The soluble isoform of CTLA-4 as a regulator of T-cell responses.
Eur J Immunol. 43 (5): 1274-85.
Further Reading
-
Chin, L.T. et al. (2008) Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.
Chang Gung Med J. 31: 1-15.
